524606 — Beryl Drugs Share Price
Last trade - 00:00- IN₹115.79m
- IN₹158.41m
- IN₹267.30m
- 49
- 41
- 10
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | 14.87 | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | 8.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.31% | ||
| Return on Equity | 0.87% | ||
| Operating Margin | 2.63% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 128.15 | 140.93 | 146.04 | 268.88 | 267.3 | n/a | n/a | 15.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -91.8 | +399.8 | n/a | n/a | -0.71 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beryl Drugs Limited is an India-based pharmaceutical manufacturing company which is principally engaged in the manufacturing of bulk drugs. The Company operates in Pharmaceutical Industry segment. In response to product requirements, it provides a variety of manufacturing options, such as small volume injectable in liquid or dry powder form, as well as a selection of eye and ear drops, intravenous (IV) fluids in glass bottles and poly packs, and veterinary medications. It is also involved in domestic, institutional and export supply. The Company uses its nationwide sales and distribution network to market a variety of branded and generic pharmaceutical formulations. Its manufacturing facility is in Pithampur, India.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 24th, 1993
- Public Since
- June 16th, 1994
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 5,071,700
- Address
- 133 KANCHAN BAG, INDORE, 452001
- Web
- https://www.beryldrugs.com/
- Phone
- +91 73125076375
- Auditors
- Subhash Chand Jain Anurag & Associates
Upcoming Events for 524606
Similar to 524606
Aayush Wellness
Bombay Stock Exchange
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
FAQ
As of Today at 19:34 UTC, shares in Beryl Drugs are trading at IN₹22.83. This share price information is delayed by 15 minutes.
Shares in Beryl Drugs last closed at IN₹22.83 and the price had moved by -34.19% over the past 365 days. In terms of relative price strength the Beryl Drugs share price has underperformed the S&P BSE 100 Index by -38% over the past year.
There is no consensus recommendation for this security.
Find out moreBeryl Drugs does not currently pay a dividend.
Beryl Drugs does not currently pay a dividend.
Beryl Drugs does not currently pay a dividend.
To buy shares in Beryl Drugs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹22.83, shares in Beryl Drugs had a market capitalisation of IN₹115.79m.
Here are the trading details for Beryl Drugs:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 524606
Based on an overall assessment of its quality, value and momentum Beryl Drugs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beryl Drugs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -32.42%.
As of the last closing price of IN₹22.83, shares in Beryl Drugs were trading -29.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beryl Drugs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹22.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Beryl Drugs' directors